SG11201700828PA - Cationic lipid - Google Patents
Cationic lipidInfo
- Publication number
- SG11201700828PA SG11201700828PA SG11201700828PA SG11201700828PA SG11201700828PA SG 11201700828P A SG11201700828P A SG 11201700828PA SG 11201700828P A SG11201700828P A SG 11201700828PA SG 11201700828P A SG11201700828P A SG 11201700828PA SG 11201700828P A SG11201700828P A SG 11201700828PA
- Authority
- SG
- Singapore
- Prior art keywords
- cationic lipid
- lipid
- cationic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/34—Esters of acyclic saturated polycarboxylic acids having an esterified carboxyl group bound to an acyclic carbon atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
- C07C229/12—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11C—FATTY ACIDS FROM FATS, OILS OR WAXES; CANDLES; FATS, OILS OR FATTY ACIDS BY CHEMICAL MODIFICATION OF FATS, OILS, OR FATTY ACIDS OBTAINED THEREFROM
- C11C3/00—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom
- C11C3/003—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom by esterification of fatty acids with alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Plant Pathology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014161718 | 2014-08-07 | ||
PCT/JP2015/072344 WO2016021683A1 (en) | 2014-08-07 | 2015-08-06 | Cationic lipid |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201700828PA true SG11201700828PA (en) | 2017-03-30 |
Family
ID=55263940
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201700828PA SG11201700828PA (en) | 2014-08-07 | 2015-08-06 | Cationic lipid |
Country Status (12)
Country | Link |
---|---|
US (1) | US10252974B2 (en) |
EP (1) | EP3178807B1 (en) |
JP (1) | JP6587619B2 (en) |
KR (1) | KR101882634B1 (en) |
CN (1) | CN106573877B (en) |
AU (1) | AU2015300046B2 (en) |
CA (1) | CA2956554C (en) |
ES (1) | ES2799409T3 (en) |
IL (1) | IL250236B (en) |
PL (1) | PL3178807T3 (en) |
SG (1) | SG11201700828PA (en) |
WO (1) | WO2016021683A1 (en) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2616051T3 (en) | 2008-12-02 | 2017-06-09 | Wave Life Sciences Japan, Inc. | Method for the synthesis of modified nucleic acids in the phosphorus atom |
US9744183B2 (en) | 2009-07-06 | 2017-08-29 | Wave Life Sciences Ltd. | Nucleic acid prodrugs and methods of use thereof |
EP2620428B1 (en) | 2010-09-24 | 2019-05-22 | Wave Life Sciences Ltd. | Asymmetric auxiliary group |
KR20140068884A (en) | 2011-07-19 | 2014-06-09 | 웨이브 라이프 사이언시스 피티이. 리미티드 | Methods for the synthesis of functionalized nucleic acids |
JP6268157B2 (en) | 2012-07-13 | 2018-01-24 | 株式会社Wave Life Sciences Japan | Asymmetric auxiliary group |
PL3094728T3 (en) | 2014-01-16 | 2022-07-04 | Wave Life Sciences Ltd. | Chiral design |
CA2980721C (en) * | 2015-03-24 | 2023-10-24 | Kyowa Hakko Kirin Co., Ltd. | Nucleic acid-containing lipid nanoparticles |
GB201604235D0 (en) * | 2016-03-11 | 2016-04-27 | Ucl Business Plc | Lipids and complexes for the delivery of biologically-active material to cells |
KR20200104360A (en) * | 2017-12-27 | 2020-09-03 | 다케다 야쿠힌 고교 가부시키가이샤 | Nucleic acid-containing lipid nano-particles and uses thereof |
EP3733641B1 (en) | 2017-12-28 | 2024-04-10 | Takeda Pharmaceutical Company Limited | Cationic lipids |
KR20200104318A (en) | 2017-12-28 | 2020-09-03 | 고쿠리츠 다이가쿠 호진 교토 다이가쿠 | Composition for target gene modification |
BR112021002384B1 (en) * | 2018-08-10 | 2024-01-23 | Takeda Pharmaceutical Company Limited | COMPOUND, LIPID PARTICLE, AND, COMPOSITION FOR NUCLEIC ACID TRANSFER |
CN112639111B (en) * | 2018-08-10 | 2023-07-21 | 国立大学法人京都大学 | Method for transfecting cardiomyocytes using cationic lipids |
JPWO2020080475A1 (en) | 2018-10-18 | 2021-09-30 | 武田薬品工業株式会社 | T cell activation / proliferation method |
JPWO2022045334A1 (en) | 2020-08-31 | 2022-03-03 | ||
CZ2020529A3 (en) * | 2020-09-23 | 2022-03-30 | Ústav organické chemie a biochemie AV ČR, v. v. i. | Lipidoids for nucleic acid transfection and their use |
CN115197080A (en) * | 2021-04-08 | 2022-10-18 | 厦门赛诺邦格生物科技股份有限公司 | Polyethylene glycol lipid and liposome modified by same, pharmaceutical composition containing liposome, preparation and application of pharmaceutical composition |
CN118201905A (en) | 2021-11-10 | 2024-06-14 | 武田药品工业株式会社 | Cationic lipid |
CN118742966A (en) | 2022-02-28 | 2024-10-01 | 武田药品工业株式会社 | Inference device, generation device, inference program, and generation program |
CN115850135B (en) * | 2022-04-29 | 2023-11-21 | 喻国灿 | Sulfur-containing Janus-type ionizable liposome and application thereof |
WO2024121814A1 (en) | 2022-12-09 | 2024-06-13 | Takeda Pharmaceutical Company Limited | Modified immunomodulators |
WO2024200820A1 (en) | 2023-03-30 | 2024-10-03 | Ose Immunotherapeutics | Method of synthesis of targeted lipid nanoparticle and uses thereof |
WO2024200823A1 (en) | 2023-03-30 | 2024-10-03 | Ose Immunotherapeutics | Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof |
WO2024210160A1 (en) | 2023-04-07 | 2024-10-10 | Takeda Pharmaceutical Company Limited | Conjugation complex |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6043390A (en) | 1998-04-03 | 2000-03-28 | The Regents Of The University Of California | Pentaerythritol lipid derivatives and nucleic-acid complexes |
KR100822684B1 (en) | 2000-10-04 | 2008-04-17 | 교와 핫꼬 고교 가부시끼가이샤 | Method of coating fine particle with lipid film |
US20040043952A1 (en) | 2002-05-31 | 2004-03-04 | Genteric, Inc. | Multifunctional polyamines for delivery of biologically-active polynucleotides |
JP2009023972A (en) * | 2007-07-23 | 2009-02-05 | Fujifilm Corp | Branched chain higher fatty acid diester derivative having diethylene triamine type metal chelate structure |
MX359674B (en) | 2008-11-10 | 2018-10-05 | Alnylam Pharmaceuticals Inc | Novel lipids and compositions for the delivery of therapeutics. |
CN101780286A (en) * | 2009-01-16 | 2010-07-21 | 中国人民解放军总医院 | Chemotactic factor receptor CXCR4 non-peptide antagonist medicaments for radiodiagnosis and treatment |
EP2567951B1 (en) | 2010-04-28 | 2018-09-19 | Kyowa Hakko Kirin Co., Ltd. | Cationic lipid |
CA2800401C (en) | 2010-06-03 | 2020-09-15 | Alnylam Pharmaceuticals, Inc. | Biodegradable lipids for the delivery of active agents |
EP2629802B1 (en) | 2010-10-21 | 2019-12-04 | Sirna Therapeutics, Inc. | Low molecular weight cationic lipids for oligonucleotide delivery |
JP6305343B2 (en) | 2011-12-07 | 2018-04-04 | アルニラム・ファーマシューティカルズ・インコーポレーテッド | Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents |
DK3988537T1 (en) * | 2011-12-07 | 2022-05-23 | Alnylam Pharmaceuticals Inc | BIODEGRADABLE LIPIDES FOR DELIVERY OF ACTIVE AGENTS |
AU2013222179B2 (en) * | 2012-02-24 | 2017-08-24 | Arbutus Biopharma Corporat ion | Trialkyl cationic lipids and methods of use thereof |
CN102898549A (en) * | 2012-10-09 | 2013-01-30 | 长沙新宇高分子科技有限公司 | Highly branched macro-molecule photoinitiator and preparation method thereof |
-
2015
- 2015-08-06 KR KR1020177006133A patent/KR101882634B1/en active IP Right Grant
- 2015-08-06 ES ES15829025T patent/ES2799409T3/en active Active
- 2015-08-06 EP EP15829025.4A patent/EP3178807B1/en active Active
- 2015-08-06 US US15/502,063 patent/US10252974B2/en active Active
- 2015-08-06 AU AU2015300046A patent/AU2015300046B2/en active Active
- 2015-08-06 CN CN201580042288.1A patent/CN106573877B/en active Active
- 2015-08-06 JP JP2016540736A patent/JP6587619B2/en active Active
- 2015-08-06 PL PL15829025T patent/PL3178807T3/en unknown
- 2015-08-06 SG SG11201700828PA patent/SG11201700828PA/en unknown
- 2015-08-06 CA CA2956554A patent/CA2956554C/en active Active
- 2015-08-06 WO PCT/JP2015/072344 patent/WO2016021683A1/en active Application Filing
-
2017
- 2017-01-23 IL IL250236A patent/IL250236B/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
EP3178807A4 (en) | 2018-03-28 |
IL250236A0 (en) | 2017-03-30 |
CN106573877A (en) | 2017-04-19 |
PL3178807T3 (en) | 2020-08-24 |
WO2016021683A1 (en) | 2016-02-11 |
IL250236B (en) | 2021-04-29 |
EP3178807A1 (en) | 2017-06-14 |
AU2015300046A1 (en) | 2017-02-16 |
US10252974B2 (en) | 2019-04-09 |
CA2956554C (en) | 2022-03-01 |
KR20170039722A (en) | 2017-04-11 |
JP6587619B2 (en) | 2019-10-09 |
CA2956554A1 (en) | 2016-02-11 |
CN106573877B (en) | 2021-04-13 |
KR101882634B1 (en) | 2018-07-26 |
US20170197903A1 (en) | 2017-07-13 |
ES2799409T3 (en) | 2020-12-17 |
JPWO2016021683A1 (en) | 2017-06-08 |
EP3178807B1 (en) | 2020-04-29 |
AU2015300046B2 (en) | 2019-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL250236A0 (en) | Cationic lipid | |
GB201707959D0 (en) | No details | |
GB201517022D0 (en) | No details | |
EP3252043A4 (en) | Cationic lipid | |
GB201519531D0 (en) | No details | |
GB201410907D0 (en) | No details | |
EP3239132A4 (en) | Cationic lipid | |
GB201517404D0 (en) | No details | |
IL262574B (en) | Cationic lipid | |
GB201418217D0 (en) | No details | |
GB201706130D0 (en) | No details | |
GB201418216D0 (en) | No details | |
EP3093283A4 (en) | Cationic lipid | |
GB201612542D0 (en) | no details | |
GB201615071D0 (en) | No details | |
GB201517412D0 (en) | No details | |
GB201709180D0 (en) | No details | |
GB201517574D0 (en) | No details | |
GB201516796D0 (en) | No details | |
GB201616225D0 (en) | No details | |
EP3162794A4 (en) | Cationic lipid | |
GB201708207D0 (en) | No details | |
GB201517605D0 (en) | No details | |
GB2523362B (en) | Turbogenerator | |
GB201702336D0 (en) | No details |